治疗原发性腋窝多汗症的新药Sofpironium bromide  

Sofpironium bromide:A new drug for primary axillary hyperhidrosis

作　　者：刘一[1] 黄琳[1] 封宇飞 刘彦国[2] LIU Yi;HUANG Lin;FENG Yu-fei;LIU Yan-guo(Department of Pharmacy,Peking University People’s Hospital,Beijing 100044,China;Department of Thoracic Surgery,Peking University People’s Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院,药学部,北京100044 [2]北京大学人民医院,胸外科,北京100044

出　　处：《中国临床药理学杂志》2022年第23期2898-2901,共4页The Chinese Journal of Clinical Pharmacology

基　　金：白求恩·求索-药学科研能力建设基金资助项目(B-19-H-20200622)。

摘　　要：于2020-09-25,日本药品和医疗器械综合管理机构正式批准5%的Sofpironium bromide凝胶用于治疗多汗症,这是日本首个批准用于治疗原发性腋窝多汗症的局部药物。Sofpironium bromide是由科研製薬株式会社研发的一种具有抗胆碱能作用的外用药物,可通过与汗腺中的M_(3)受体结合进而减少出汗。本文现从Sofpironium bromide的药理研究、药代动力学、临床研究、安全性等方面进行综述,以全面介绍该药的研究现状和已有成果。On September 25,2020,Pharmaceuticals and Medical Devices Agency(PMDA)officially approved 5%Sofpironium bromide gel for the treatment of hyperhidrosis.This is the first topical product approved for the treatment of primary axillary hyperhidrosis in Japan.Sofpironium bromide is a topical drug with anticholinergic effect developed by Kaken Pharmaceutical Co.,Ltd.It can reduce sweating by binding to M_(3)receptor in the sweat gland that causes hyperhidrosis.The pharmacological study,pharmacokinetics,clinical research,and safety of Sofpironium bromide are reviewed to comprehensively introduce the research status and existing achievements of Sofpironium bromide.

关 键 词：原发性腋窝多汗症 Sofpironium bromide 临床研究 安全性 

分 类 号：R97[医药卫生—药品]